Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated growth of synchronous colorectal liver metastases: effects of neo-adjuvant therapy
2006-005197-51Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bevacizumab in colorectal cancer (CRC) and hepatic metastasis, sponsored by Netherlands Cancer Institute. Primary endpoint: Relative change in SUV of liver metastases on PET-CT after 9 weeks. Started Jun 2008; status: active.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)hepatic metastasis
Beyond the preview
Go deeper on 2006-005197-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005197-51.